Lipidemia Clinical Trials

129 recruitingLast updated: June 18, 2026

There are 129 actively recruiting lipidemia clinical trials across 34 countries. Studies span Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4, Early Phase 1. Top locations include Seoul, South Korea, Beijing, Beijing Municipality, China, Beijing, China. Updated daily from ClinicalTrials.gov.


Lipidemia Trials at a Glance

129 actively recruiting trials for lipidemia are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Not Applicable with 54 trials, with the heaviest enrollment activity in Seoul, Beijing, and Beijing. Lead sponsors running lipidemia studies include University of Georgia, NewAmsterdam Pharma, and Yonsei University.

Treatments under study

About Lipidemia Clinical Trials

Looking for clinical trials for Lipidemia? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lipidemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lipidemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 129 trials

Recruiting
Not Applicable

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

DyslipidemiasPeripheral Vascular DiseasesPeripheral Artery Disease
Brigham and Women's Hospital400 enrolled1 locationNCT06300450
Recruiting
Not Applicable

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Cardiovascular DiseasesAtherosclerosisDyslipidemia+2 more
Yonsei University1,952 enrolled1 locationNCT07524101
Recruiting
Phase 3

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Hyperlipidemia
Merck Sharp & Dohme LLC975 enrolled89 locationsNCT07216482
Recruiting

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

mixed dyslipidemiaPrimary Hypercholesterolemiia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,000 enrolled163 locationsNCT06686615
Recruiting
Phase 3

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Hypercholesterolaemiamixed dyslipidemia
A. Menarini International Licensing S.A.426 enrolled1 locationNCT07614958
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting

Regional Innovation in Chronic Disease and Elderly Care

HypertensionCardiovascular DiseaseHyperglycemia+1 more
Fu Jen Catholic University1,000 enrolled1 locationNCT07578090
Recruiting
Not Applicable

Uppsala Self-Screening of Cardiovascular Health (U-SCREEN)

Diabetes MellitusCardiovascular DiseasesAtrial Fibrillation+3 more
Johan Sundström45,000 enrolled1 locationNCT07614659
Recruiting
Phase 1

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Not Applicable

Social Needs Screening and Chronic Diseases Study (WE CARE)

DepressionHypertensionDiabetes+2 more
University of Massachusetts, Worcester68,000 enrolled3 locationsNCT06903897
Recruiting
Not Applicable

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

Cardiovascular DiseasesInflammationDyslipidemias
Universidade Federal Fluminense48 enrolled1 locationNCT06183307
Recruiting
Not Applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

PrediabetesPrehypertensionOverweight/Obesity+1 more
Beijing Anzhen Hospital1,400 enrolled3 locationsNCT07372729
Recruiting
Phase 3

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Hyperlipidemia
Beijing Suncadia Pharmaceuticals Co., Ltd900 enrolled1 locationNCT07230730
Recruiting
Not Applicable

New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases

HypertensionCardiovascular Disease PreventionHyperlipidemia+5 more
New Taipei City Medical Association4,162 enrolled1 locationNCT07588256
Recruiting
Phase 1

A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function

Hyperlipidemias
Shandong Suncadia Medicine Co., Ltd.36 enrolled1 locationNCT07322016
Recruiting
Not Applicable

Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT

Cardiovascular DiseasesHeart DiseasesCoronary Artery Disease+7 more
Prof. Maurovich-Horvat Pál140 enrolled1 locationNCT06603363
Recruiting
Phase 4

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Diabetes Mellitus, Type 2AtherosclerosisDyslipidemias
Seoul National University Bundang Hospital105 enrolled1 locationNCT05365438
Recruiting
Phase 4

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Diabetes Mellitus, Type 2AtherosclerosisDyslipidemia
Seoul National University Bundang Hospital56 enrolled1 locationNCT05365425
Recruiting
Not Applicable

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients

Diabetes MellitusHypertensionDyslipidemia
Xiong Juyang600 enrolled1 locationNCT07552571
Recruiting

Psychosocial, Environmental, and Chronic Disease Trends in Puerto Rico

ObesityCardiovascular DiseasesMetabolic Syndrome+13 more
Harvard School of Public Health (HSPH)2,500 enrolled1 locationNCT03794531